Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug:41:12-19.
doi: 10.1016/j.coph.2018.04.003. Epub 2018 Apr 17.

Autophagy as a cytoprotective mechanism in esophageal squamous cell carcinoma

Affiliations
Review

Autophagy as a cytoprotective mechanism in esophageal squamous cell carcinoma

Timothy M Hall et al. Curr Opin Pharmacol. 2018 Aug.

Abstract

Esophageal squamous cell carcinoma (ESCC) is amongst the most aggressive human malignancies, representing a significant health burden worldwide. Autophagy is an evolutionarily conserved catabolic process that degrades and recycles damaged organelles and misfolded proteins to maintain cellular homeostasis. Alterations in autophagy are associated with cancer pathogenesis, including ESCC; however, the functional role of autophagy in ESCC remains elusive. Here, we discuss the clinical relevance of autophagy effectors in ESCC and review current knowledge regarding the molecular mechanisms through which autophagy contributes to ESCC. We highlight the cytoprotective role of autophagy in ESCC and discuss autophagy inhibitors as novel experimental therapeutics to potentiate the effects of anti-cancer therapies and/or to overcome therapeutic resistance in ESCC.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

None.

Figures

Figure 1
Figure 1. Autophagy is a tumor promoting factor in ESCC
Autophagy activation has been documented in esophageal squamous cell carcinoma (ESCC) cells in response to both endogenous and exogenous stimuli. Metastasis-associated colon cancer 1 (MACC1)-mediated induction of autophagy promotes ESSC cell proliferation, migration and invasion. Transforming growth factor (TGF)-β in the tumor microenvironment induces autophagy to promote expansion of CD44High cancer stem cells (CSCs). Autophagy also promotes expansion of OV6+ CSCs via Wnt/β-catenin signaling; however, the mechanisms regulating autophagy activation in this context remain to be determined. Activation of autophagy by chemo- and radiotherapy as well as various experimental ESCC therapeutics induce autophagy that has largely been shown to act in a cytoprotective fashion to limit therapy-induced cell death and promote therapy resistance.
Figure 2
Figure 2. Strategies for pharmacological autophagy inhibition
Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) act at the lysosome to prevent autophagic vesicle (AV) clearance. Clinical trials using CQ or HCQ have been executed for various cancer types with varying results in terms of both patient outcomes and effects on autophagy in tumor tissues. Lys05, a dimeric analog of CQ, exhibits increased potency with regard to single-agent antitumor activity and autophagy inhibition as compared to HCQ in preclinical models; however, the clinical utility of this agent has yet to be established. Inhibitors of more proximal steps in autophagy have been utilized in preclinical studies, including those targeting unc-51-like kinase 1 (ULK1) and the class III phosphoinositide 3-kinase VPS34, two positive effectors of AV nucleation, and the cysteine protease ATG4B, a mediator of AV elongation. As these agents are further developed, it will be of great interest to determine their effects on human tumors either alone or in combination with established therapeutic modalities. This is particularly true of esophageal squamous cell carcinoma in which current data supports a tumor promoting role for autophagy and therapeutic resistance represents as substantial clinical challenge.

Similar articles

Cited by

References

    1. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499–2509. - PubMed
    1. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173–1180. - PubMed
    1. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–95. - PubMed
    1. Network CGAR, University AWGA, Agency BC, et al. Hospital BaWs, Institute B, University B, University CWR, Institute D-FC, University D, Centre GPC. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–175. The authors perform comprehensive molecular analysis of 164 esophageal tumors, identifying three distinct molecular subtypes of ESCC, two of which featured deep deletions in ATG7 in up to 25% of cases. - PMC - PubMed
    1. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990;87:9958–9961. - PMC - PubMed

Publication types

MeSH terms

Substances